Remarkable Response of Primary Squamous Cell Carcinoma of the Ovary to Paclitaxel and Cisplatin

G Eltabbakh, G H Eltabbakh, R E Hempling, F O Recio, C P O'Neill
Obstetrics and gynecology · 1998 · vol. 91(5) , pp. 844–846 · doi:10.1016/s0029-7844(97)00665-0 · PMID:9572185 · W2055405051
article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

A patient with stage IV primary ovarian squamous cell carcinoma and hepatic metastases experienced a dramatic response and remains disease-free for 2 years after cytoreductive surgery followed by paclitaxel and cisplatin chemotherapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: The survival rate of patients with advanced stage primary squamous cell carcinoma of the ovary is dismal and the best treatment is unknown. We describe the response of this tumor to systemic chemotherapy employing paclitaxel and cisplatin. CASE: A 31-year-old white woman diagnosed with International Federation of Gynecology and Obstetrics stage IV primary squamous cell carcinoma of the ovary associated with ovarian endometriosis underwent cytoreductive surgery followed by paclitaxel and cisplatin every 4 weeks for 12 courses. The patient tolerated chemotherapy well, demonstrated a dramatic response with disappearance of hepatic metastases, and remains without evidence of disease 2 years after diagnosis. CONCLUSION: Paclitaxel and cisplatin may be effective in treating primary squamous cell carcinoma of the ovary.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antineoplastic Combined Chemotherapy Protocols Carcinoma, Squamous Cell Ovarian Neoplasms Adult Antineoplastic Combined Chemotherapy Protocols Carcinoma, Squamous Cell Carcinoma, Squamous Cell Carcinoma, Squamous Cell Cisplatin Cisplatin Combined Modality Therapy Female Humans Liver Neoplasms Liver Neoplasms Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Paclitaxel Paclitaxel

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (7)

Cited by (7)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:10:40.754221+00:00
unpaywall
last seen: 2026-06-06T02:00:05.402940+00:00
License: CC0 · commercial use OK